The BioMed X Institute
A new research team at XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
RIDGEFIELD, CT / ACCESSWIRE / June 5, 2024 / XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut. This research team's main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently.
The new research team is led by Dr. Lorenzo Talà, Group Leader at XSeed Labs. "Due to insufficient understanding of the mechanisms driving their pathology, therapies to treat fibrotic diseases are limited. The aim of our research group is to develop physiologically relevant in vitro and in silico fibrosis models. By combining both approaches, we will interrogate disease mechanisms, identify drug delivery pathways, and assess drug safety in order to facilitate drug development toward resolving fibrotic tissues."
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "We are pleased that we could successfully translate the innovation model we established in Heidelberg and New Haven to work inside a major pharma research and development campus. We have a long history of successful collaboration with Boehringer Ingelheim at our Heidelberg institute, and we are proud to extend this collaboration to their U.S. headquarters in Ridgefield, Connecticut."
"We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases," said Carine Boustany, PhD, U.S. Research Site Head and Global Head of Immunology and Respiratory Diseases Research, Boehringer Ingelheim. "In parallel, we will harness these innovative disease model systems to assess the safety of novel anti-fibrotic concepts, and identify better ways to deliver our molecules," said Xiaorong He, PhD, U.S. Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim.
"We are excited to start our first XSeed Labs team at Boehringer Ingelheim in Ridgefield. It is the beginning of a unique innovation model that promotes scientific exchange between major players in biomedical research," says Mark Johnston, CEO of BioMed X USA.
About BioMed X and XSeed Labs
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds -- academia and industry -- and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model - called XSeed Labs - entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27
Related Images
SOURCE: BioMed X Institute & XSeed Labs
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Polaris Renewable Energy Announces Q3 2025 Results30.10.2025 12:50:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 30, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the nine and three months ended September 30, 2025. This earnings release should be read in conjunction with the Company's condensed consolidated interim financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. 2025 HIGHLIGHTS Third quarter consolidated energy production totaled 181,235 MWh, representing a 7% increase compared to 168,639 MWh in the same quarter last year. The increase is mainly attributable to the contribution from the Puerto Rican wind farm, acquired on March 3, 2025, which was not part of the portfolio in the comparative quarter of 2024, as well as stronger hydrologi
Polaris Renewable Energy Declares Quarterly Dividend30.10.2025 12:50:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 30, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on November 21st to shareholders of record at the close of business on November 10th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Compan
Camino and Nittetsu Commence Proprietary Leaching Studies for Growth Opportunities at the Puquios Copper Project in Chile30.10.2025 11:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / October 30, 2025 / :Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that its joint venture with Nittetsu Mining Co., Ltd. ("Nittetsu") will initiate leaching studies at Nittetsu's metallurgical and chemical facility in Tokyo. These studies aim to assess the scalability of the Puquios Copper Project ("Puquios"or the "Project"). The Puquios mine is planned as a conventional sulphide leaching operation utilizing solvent extraction and electro winning ("SXEW") technology. All permits required for commencement of construction are in place, with mine construction anticipated in the first half of 2026. To support development, Camino and Nittetsu are actively pursuing a debt facility with a Japanese lender that is expected to offer highly competitive terms in the current mining finance environment. The first stage of the Puquios copper mine development is now on a path towards production. The Company is ev
Investment Firm Alpha Star invests 1 million USD in AI Art Authentication Company Art Recognition29.10.2025 11:00:00 CET | Press release
ZURICH, SWITZERLAND / ACCESS Newswire / October 29, 2025 / Art Recognition , the Swiss pioneer in AI art authentication, is delighted to announce a new strategic partnership with Alpha Star , a leading Luxembourg-based investment fund with a strong track record of supporting innovative companies in the art market. This collaboration marks an important milestone as Alpha Star becomes Art Recognition's anchor investor. The partnership will accelerate Art Recognition's growth and strengthen its position as a trusted technology partner for the art world, helping bring greater transparency, confidence, and innovation to art authentication. "We are thrilled to welcome Alpha Star as a key partner on our journey," said Carina Popovici, CEO and Founder of Art Recognition. "Their confidence in our technology and vision is a strong endorsement of the role AI will play in shaping the future of the art world." "We are excited to support Art Recognition in its mission to bring cutting-edge AI techno
Ecological Threat Report 2025: Extreme Wet-Dry Seasons Emerge as Critical Conflict Catalyst29.10.2025 06:00:00 CET | Press release
Approximately 2 billion people - one quarter of humanity - now live in regions experiencing moderate to severe increases in seasonality LONDON, GB / ACCESS Newswire / October 29, 2025 / New research from the Institute for Economics & Peace reveals that changing rainfall patterns are significantly amplifying conflict risks worldwide. The 2025 Ecological Threat Report (ETR), released today, finds conflict death rates are substantially higher in areas where rainfall is concentrating into fewer months, compared to regions where rain is spreading more evenly throughout the year.Ecological Threat Report 2025 Analysing Ecological Threats, Resilience & Peace Key Findings On average in areas where wet and dry seasons are becoming more extreme, there are four times as many conflict deaths as areas where it has decreased. In 2024, natural hazards triggered 45 million short-term internal displacements across 163 countries, the highest figure since at least 2008. Western Brazil, including parts of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom